Cellectis (CLLS) Interest Expenses (2015 - 2026)
Cellectis (CLLS) posted quarterly Interest Expenses of -$4.4 million for Q1 2026, up 56.63% year-over-year from -$2.8 million in Q1 2025, and down 104.9% quarter-over-quarter from $90.7 million in Q4 2025.
Cellectis (CLLS) Interest Expenses (2015 - 2026) Analysis & Trends
Cellectis' Interest Expenses history runs 12 years deep, the most recent figure standing at -$4.4 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 56.63% year-over-year to -$4.4 million; the TTM figure through Mar 2026 stood at $55.7 million (up 1555.4% YoY), while the FY2025 annual figure was $51.1 million, up 136.25% from the prior year.
- Interest Expenses for Q1 2026 stood at -$4.4 million, down from $90.7 million in the prior quarter.
- The five-year high for Interest Expenses was $90.7 million in Q4 2025, with the low at -$19.7 million in Q2 2025.
- The 5-year median for Interest Expenses is -$3.1 million (2024), against an average of $8.2 million.
- The sharpest annual moves came in 2022 and 2023: Interest Expenses plunged 1134.55% in 2022, then jumped 2221.78% in 2023.
- Cellectis' Interest Expenses stood at $22.0 million in 2022, then jumped by 190.28% to $63.7 million in 2023, then decreased by 28.35% to $45.7 million in 2024, then jumped by 98.68% to $90.7 million in 2025, then sank by 104.9% to -$4.4 million in 2026.
- Business Quant data shows CLLS's Interest Expenses at -$4.4 million in Q1 2026, $90.7 million in Q4 2025, and -$10.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | -4.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.44 Mn |
| Mar 31, 2026 | -4.44 Mn |
| Dec 31, 2025 | 90.72 Mn |
| Dec 31, 2025 | 90.72 Mn |
| Sep 30, 2025 | -10.91 Mn |
| Sep 30, 2025 | -10.91 Mn |
| Jun 30, 2025 | -19.70 Mn |
| Jun 30, 2025 | -19.70 Mn |
| Mar 31, 2025 | -10.25 Mn |
| Mar 31, 2025 | -10.25 Mn |
| Dec 31, 2024 | 45.66 Mn |
| Dec 31, 2024 | 45.66 Mn |
| Sep 30, 2024 | -15.41 Mn |
| Sep 30, 2024 | -15.41 Mn |
| Jun 30, 2024 | -16.65 Mn |
| Jun 30, 2024 | -16.65 Mn |
| Mar 31, 2024 | -3.14 Mn |
| Mar 31, 2024 | -3.14 Mn |
| Dec 31, 2023 | 63.73 Mn |
| Dec 31, 2023 | 63.73 Mn |